EcoDrugPlus

Potassium Intermediate/small Conductance Calcium-Activated Channel, Subfamily N, Member 4

Ensembl ID : ENSMSIG00000000335
Gene Symbol: KCNN4
1 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel, Subfamily J, Member 11

Ensembl ID : ENSMSIG00000026521
Gene Symbol: KCNJ11
1 Cross references
204 Possible Orthologues:

Potassium Inwardly-Rectifying Channel, Subfamily J, Member 2

Ensembl ID : ENSMSIG00000017323
Gene Symbol: KCNJ2
1 Cross references
292 Possible Orthologues:

Potassium Inwardly-Rectifying Channel, Subfamily J, Member 3

Ensembl ID : ENSMSIG00000022910
Gene Symbol: KCNJ3
1 Cross references
234 Possible Orthologues:

Potassium Inwardly-Rectifying Channel, Subfamily J, Member 5

Ensembl ID : ENSMSIG00000010116
Gene Symbol: KCNJ5
1 Cross references
220 Possible Orthologues:

Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1

Ensembl ID : ENSMSIG00000017175
Gene Symbol: KCNMA1
1 Cross references
299 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Family, Member 3

Ensembl ID : ENSMSIG00000005944
Gene Symbol: KCND3
1 Cross references
274 Possible Orthologues:

Potassium Voltage-Gated Channel, Shaker-Related Subfamily, Member 5

Ensembl ID : ENSMSIG00000025136
Gene Symbol: KCNA5
1 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2

Ensembl ID : ENSMSIG00000003575
Gene Symbol: KCNH2
1 Cross references
267 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily Q, Member 2

Ensembl ID : ENSMSIG00000013491
Gene Symbol: KCNQ2
1 Cross references
263 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily Q, Member 3

Ensembl ID : ENSMSIG00000011752
Gene Symbol: KCNQ3
1 Cross references
206 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily Q, Member 5

Ensembl ID : ENSMSIG00000020039
Gene Symbol: KCNQ5
1 Cross references
293 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).